NUE20798

NUE20798 is a preclinical **small-molecule, BET bromodomain selective inhibitor** developed by Nuevolution. Public disclosures describe it as a **BET-BD1 selective bromodomain inhibitor**, meaning it is designed to preferentially engage the first bromodomain of BET family epigenetic reader proteins rather than acting as a nonselective pan-BET inhibitor. The program was explored in animal models for **atopic dermatitis** and in combination with **anti-PD-1 immunotherapy** in colorectal cancer models, with the proposed biology involving modulation of BET-driven transcriptional programs and anti-fibrotic or immunomodulatory effects. Available public information indicates that the asset remained in **preclinical development** and there is no evidence of marketing approval.